SUBSCRIBE
SUBSCRIBE
News   Business

Andromeda Says Teva Pharmaceutical Industries Limited to Market Diabetes Treatment

June 22, 2009 | 
1 min read

Bookmark and Share

Reuters -- Israel’s Andromeda Biotech said on Monday Teva Pharmaceutical Industries had decided to exercise its option to complete a $13.5 million investment to market Andromeda’s treatment for Type I diabetes.

Alliances Asia
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Cellectar Downsizes by 60% as it Explores Strategic Options for Cancer Drug
December 11, 2024
 · 
202 min read
 · 
BioSpace Editorial Staff
Podcast
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
December 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Group Of Employees Being Fired By Their Company.
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
December 10, 2024
 · 
2 min read
 · 
Angela Gabriel
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
December 9, 2024
 · 
1 min read
 · 
Heather McKenzie